相关实验视频

Updated: Jul 27, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

一个第一阶段的多重剂量研究提尔泽帕提德在中国患者的2型糖尿病

Ping Feng^1,2, Xiaoyan Sheng³, Yongjia Ji⁴

¹Department of Pharmacy, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, 610041, Sichuan, People's Republic of China.

Advances in therapy

|June 7, 2023

概括

蒂尔泽帕提德在中国2型糖尿病患者中显示出良好的安全性和耐受性. 这项研究支持其用于每周剂量的使用,显示HbA1c和体重的改善.

科学领域:

药理学和内分泌学药理学和内分泌学
临床试验研究临床试验研究

背景情况:

2型糖尿病 (T2D) 在全球范围内构成了重大健康挑战,特别是在多元种族的人群中.
了解不同种族群体对新型治疗方法的具体反应对于个性化医学至关重要.

研究的目的:

评估特泽帕提德的安全性,耐受性,药理动力学 (PK) 和药理动力学 (PD) 在被诊断为T2D的中国患者中.
为了确定tirezepatide在这个特定的患者群体中适合每周一次的皮下注射.

主要方法:

这是一项1期,双盲,安慰剂控制,多剂量研究,涉及中国2型糖尿病患者.
随机划分为两个群体,接受逐渐增加的蒂尔泽帕提德剂量 (2.5-10.0毫克或2.5-15.0毫克) 或安慰剂,每周服用一次皮下注射.
主要结局评估侧重于在整个研究期间对蒂尔泽帕提德的安全性和耐受性.

主要成果:

蒂尔泽帕提德的耐受性一般很好,最常见的是轻微的短暂不良事件,如腹和食欲下降.
在提尔泽帕提德组中没有报告任何严重不良事件,血半衰期约为5-6天.
与安慰剂相比,在tirzepatide接受者中观察到HbA1c (高达-2.4%),体重 (高达-6.7公斤) 和空腹血葡萄糖的显著降低.

结论:

蒂尔泽帕提德在中国2型糖尿病患者中表现出良好的安全性和耐受性.
观察到的药理动力学和药理动力学特征支持每周服用一次剂量方案的有效性和安全性.
这些发现为进一步研究为这个人群进行更大规模的临床试验提供了强有力的基础.

关键词:

在GIP的基础上,GIP是GIP.这就是GLP-1.药理动力学是什么药理动力学药理动力学药理动力学第1阶段第一阶段蒂尔泽帕提德是什么意思 2 型糖尿病 2 型糖尿病

更多相关视频

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

相关概念视频

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Clinical Trials

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...